1. Home
  2. PRG vs DVAX Comparison

PRG vs DVAX Comparison

Compare PRG & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PROG Holdings Inc.

PRG

PROG Holdings Inc.

HOLD

Current Price

$29.75

Market Cap

1.4B

ML Signal

HOLD

Logo Dynavax Technologies Corporation

DVAX

Dynavax Technologies Corporation

HOLD

Current Price

$10.83

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRG
DVAX
Founded
2020
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.3B
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
PRG
DVAX
Price
$29.75
$10.83
Analyst Decision
Buy
Buy
Analyst Count
6
4
Target Price
$35.00
$26.50
AVG Volume (30 Days)
477.8K
1.5M
Earning Date
10-22-2025
11-05-2025
Dividend Yield
1.71%
N/A
EPS Growth
10.59
N/A
EPS
3.96
N/A
Revenue
$2,507,179,000.00
$330,514,000.00
Revenue This Year
$1.32
$24.63
Revenue Next Year
$0.64
$15.85
P/E Ratio
$7.67
N/A
Revenue Growth
3.71
26.73
52 Week Low
$23.50
$9.20
52 Week High
$48.77
$14.63

Technical Indicators

Market Signals
Indicator
PRG
DVAX
Relative Strength Index (RSI) 51.87 48.18
Support Level $28.88 $10.76
Resistance Level $31.52 $11.00
Average True Range (ATR) 1.02 0.25
MACD 0.22 -0.06
Stochastic Oscillator 56.21 20.53

Price Performance

Historical Comparison
PRG
DVAX

About PRG PROG Holdings Inc.

PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Share on Social Networks: